<DOC>
	<DOCNO>NCT00114127</DOCNO>
	<brief_summary>The purpose study examine safety efficacy duloxetine treatment social anxiety disorder .</brief_summary>
	<brief_title>Duloxetine Social Anxiety Disorder : Prediction Long Term Outcome</brief_title>
	<detailed_description>An expand body clinical experience control trial establish efficacy serotonin selective reuptake inhibitor ( SSRIs ) serotonin norepinephrine reuptake inhibitor ( SNRI ) venlafaxine , treatment social anxiety disorder , paroxetine , sertraline venlafaxine extended-release ( XR ) , FDA approve indication . The new SNRI , duloxetine , show effective dos 60mg/day 120mg/day anxiety associate depression , anticipate broad spectrum agent mood anxiety disorder ( Dunner , Goldstein , Mallinckrodt , Lu , &amp; Detke , 2003 ) . However , data efficacy duloxetine Social Anxiety Disorder , guidance regard time response predictor response , yet available . These question focus proposal . This two phase , 24-week research study participant remain symptomatic end one phase ( 6 week ) enter next phase . In phase I , participant receive 60mg/day duloxetine ( Cymbalta ) 6 week . Participants continue anxiety symptom enter 18-week Phase II , continue take 60 mg/day duloxetine also randomly assign ( chance , like flip coin ) receive either additional 60mg/day duloxetine placebo ( contains active medication ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male female outpatient &gt; 18 year age primary psychiatric diagnosis generalize social anxiety disorder define DSMIV criterion LSAS score &gt; 50 . Physical examination , electrocardiogram , laboratory finding without clinically significant abnormality . Willingness ability comply requirement study protocol . Patient history intolerance lack response treatment trial duloxetine high tolerate dose ( &lt; 120mg/day ) . Patients acute narrow angle glaucoma . Pregnant woman , lactate woman , woman childbearing potential use medically accept form contraception ( e.g. , IUD , oral contraceptive , barrier device , condom foam , implant progesterone rod stabilize least 3 month ) . Concurrent use psychotropic medication . Patients must discontinue regular benzodiazepine antidepressant therapy least one week ( 5 week fluoxetine ) prior baseline . Concomitant betablockers proscribe unless prescribe medical indication ( e.g. , hypertension , stable daily dose &gt; 1 month ) . Patients history failure satisfactorily respond &gt; 2 prior adequate treatment trial . Significant personality dysfunction likely interfere study participation . Serious medical illness instability hospitalization may likely within next year . Seizure disorder exception history febrile seizure occur childhood , isolate , recur adulthood . Concurrent psychotherapy initiate within 2 month baseline prohibit . Ongoing psychotherapy duration direct specifically toward treatment social anxiety disorder exclude . Prohibited psychotherapy include cognitive behavioral therapy psychodynamic therapy focus explore specific , dynamic cause phobic symptomatology provide skills management . General supportive individual , couple , family therapy great 2 month duration acceptable . Diagnosis follow mental disorder define DSMIV : lifetime history schizophrenia psychosis , mental retardation , organic medical disorder bipolar disorder ; eat disorder past 6 month ; alcohol substance abuse past 3 month dependence within past 6 month . Entry patient major depression , dysthymia , panic disorder , generalize anxiety disorder , posttraumatic stress disorder obsessivecompulsive disorder permit social anxiety disorder judge predominant disorder , order increase accrual clinically relevant sample . Patients significant suicidal ideation ( MADRS item 10 score &gt; 3 ) enact suicidal behavior within 6 month prior intake exclude study participation refer appropriate clinical intervention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>social anxiety disorder</keyword>
	<keyword>social phobia</keyword>
	<keyword>duloxetine</keyword>
	<keyword>serotonin norepinephrine reuptake inhibitor</keyword>
	<keyword>SNRI</keyword>
	<keyword>double blind</keyword>
</DOC>